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Abstract
Most pre-clinical therapy studies use the change in tumor volume as a measure for disease 
response. However, tumor size measurements alone may not reflect early changes in tumor 
physiology that occur as a response to treatment. Ultrasonic molecular imaging (USMI) and 
Dynamic Contrast Enhanced - Perfusion Imaging (DCE-PI) with ultrasound are two attractive 
alternatives to tumor volume measurements. Since these techniques can provide information prior 
to the appearance of gross phenotypic changes, it has been proposed that USMI and DCE-PI could 
be used to characterize response to treatment earlier than traditional methods. This study evaluated 
the ability of tumor volume measurements, DCE-PI, and USMI to characterize response to therapy 
in two different types of patient-derived xenografts (known responders and known non-
responders). For both responders and non-responders, 7 animals received a dose of 30 mg/kg of 
MLN8237, an investigational aurora-A kinase inhibitor, for 14 days or a vehicle control. 
Volumetric USMI (target integrin: αvβ3) and DCE-PI were performed on day 0, day 2, day 7, and 
day 14 in the same animals. For USMI, day 2 was the earliest point at which there was a statistical 
difference between the untreated and treated populations in the responder cohort (Untreated: 
1.20±0.53 vs. Treated: 0.49±0.40; p < 0.05). In contrast, statistically significant differences 
between the untreated and treated populations as detected using DCE-PI were not observed until 
day 14 (Untreated: 0.94±0.23 vs. Treated: 1.31±0.22; p < 0.05). Volume measurements alone 
suggested no statistical differences between treated and untreated populations at any readpoint. 
Monitoring volumetric changes is the “gold standard” for evaluating treatment in pre-clinical 
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studies, however, our data suggests that volumetric USMI and DCE-PI may be used to earlier 
classify and robustly characterize tumor response.
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Introduction
Aurora-A Kinase Inhibition
Aurora kinase, a type of serine/threonine kinase, is part of a family of enzymes related to 
cell proliferation (1). In the mid 1990’s, it was discovered that aurora kinase defects led to 
mitotic abnormalities (2). Disruption of the functional process involving aurora kinase can 
result in mitotic spindle apparatus deficiencies, chromosome segregation abnormalities and 
eventually apoptosis (3). The discovery that aurora kinases are highly expressed in many 
tumor cell lines, including pancreatic adenocarcinoma (4), has led to the development of a 
variety of aurora kinase inhibitors, such as MLN8237, for tumor research (5, 6, 7). 
MLN8237, an orally administered aurora-A kinase inhibitor is currently in clinical trials for 
patients with advanced solid tumors; emerging data suggests that it may be active in some 
adult solid tumors (8)(9).
Response to therapy
Anatomic measures of solid tumors have been the “gold standard” by which therapy 
effectiveness is evaluated (10). The disadvantage to using size measurements to analyze 
response is that although the tumor volume may not have changed significantly, there may 
be considerable changes in tumor activity and necrosis (11, 12). In many instances, there 
may be a significant delay or lag time between the time of treatment and any change in 
tumor size (10). Thus, new early imaging response techniques are sought after to non-
invasively predict treatment response both clinically and pre-clinically. Ultrasonic molecular 
imaging (USMI) and Dynamic Contrast Enhanced - Perfusion Imaging (DCE-PI) are two 
attractive alternatives.
Ultrasonic Molecular Imaging
USMI has the ability to non-invasively characterize biologic processes at the cellular and 
molecular level (13, 14, 15). The principle behind USMI is the selective targeting of 
acoustically active intravascular microbubble contrast agents (MCAs) to biomarkers 
expressed on the endothelium (16). Once accumulated at the target site, the MCAs enhance 
the acoustic backscatter from pathologic tissue that might otherwise be difficult to 
distinguish from normal tissues. While USMI is still a developing field, a wide variety of 
techniques are emerging such as assessment of tumor angiogenesis, the diagnosis of 
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myocarditis, the evaluation of transplant rejection, the evaluation of cardiovascular disease, 
and the imaging of dysfunctional endothelium, and thrombus (17, 14, 18, 19).
MCAs are inherently blood pool agents, thus USMI is restricted to analysis of biological 
events located within the vascular system. This particular characteristic makes this imaging 
modality an attractive non-invasive technique for the detection of molecular processes on 
vascular endothelial cells, and more specifically, tumor angiogenesis. Tumor angiogenesis is 
the formation of capillaries and new blood vessels from surrounding host tissue to provide 
sufficient oxygen supply and nutrients to the tumor (20). As cancer cells proliferate, more 
oxygen and nutrients are needed for cell survival. Thus, at the onset of hypoxia after cell 
proliferation, tumors will assemble vasculature by releasing chemotactic signals to recruit 
endothelial precursor cells (20). Presumably, any impairment of tumor growth and apoptosis 
has a downstream effect on angiogenesis and therefore angiogenic integrins (VEGFR-2, 
αvβ3, etc.) expressed on endothelial cells in proximity to the tumor (21, 22).
In recent years, targeted agents have been successfully used for non-invasive two-
dimensional in vivo imaging of tumor angiogenesis (23, 24, 25, 26, 27), and more recently 
USMI has been demonstrated in 3-D (28, 29). This breakthrough has allowed USMI to be 
used for quantifying the efficacy of anti-angiogenic drugs such as bevacizumab (VEGF 
inhibitor) in murine models (26, 30, 31).
Dynamic Contrast Enhanced - Perfusion Imaging
Ultrasound DCE-PI is a method that is used to non-invasively monitor the blood flow in 
both large vessels and in the capillary microcirculation using non-targeted MCAs. This 
technique uses a short high-intensity pulse of ultrasound that causes rapid destruction of 
MCAs in the interrogated region. This clearance pulse is immediately followed by a low-
intensity contrast specific signal that does not fracture the microbubbles, but instead, allows 
for the pixel-by-pixel observation of blood flow rates as the MCAs enter back into the tissue 
(32, 33). Accordingly, changes in contrast enhancement over time can provide information 
about tissue perfusion. This method has previously been utilized to assess perfusion in the 
myocardium, kidney, and other tissues (33, 34, 32). Furthermore, it is hypothesized that 
tissue perfusion correlates to tumor micro vessel density (MVD) (35, 36), a known 
prognostic factor in many cancer types (37, 38), which has been the motivation for the 
development of this technique in cancer assessment. Thus, it is proposed that in vivo 
measures using DCE-PI may also predict therapeutic response to agents that target and 
disrupt the tumor microvasculature.
It is unknown as to what method provides the best opportunity for successful pre-clinical 
evaluations, though our hypothesis predicts that USMI will provide information earlier in 
the treatment schedule than both DCE-PI and volume measurements. A recent study by Sirsi 
et al, which aimed to evaluate both molecular imaging and perfusion imaging in a response 
to therapy study (VEGF Inhibition in SK-NEP-1 tumor line), supports our hypothesis (39). 
Although this study was performed only with 2-D ultrasound, it was highly significant in 
suggesting the potential of DCE-PI and USMI in the evaluation of a tumor’s response to 
therapy. As recent studies have illustrated that 3-D ultrasound DCE-PI and 3-D USMI 
provide more accurate data regarding tissue blood flow and biomarker distribution than 2-D 
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ultrasound, it is crucial to validate these technologies with volumetric imaging (28, 40, 41). 
Thus, the aim of this study is to further validate the potential of USMI and DCE-PI in 
characterizing a tumor’s response to therapy using 3-D ultrasound.
To test our hypothesis, we use USMI of angiogenesis and DCE-PI, both implemented in 3-
D, to evaluate the effect of MLN8237 in patient-derived xenografts (PDX) of pancreatic 
cancer. PDX models of solid tumors have recently emerged as an innovative platform for the 
study of novel therapeutics for pancreatic cancer (42). This model, where actual human 
tumors are grafted into mice, has been shown to be a better predictor of response to therapies 
in patients compared to traditional cell line xenografts (43). We use a Siemens Sequoia 
ultrasound system (Mountain View, CA) in Cadence Pulse Sequencing (CPS) mode for both 
perfusion and molecular imaging studies. In addition, with the use of a custom computer-
controlled motion stage interfaced to the ultrasound system, we perform volumetric imaging 
by scanning the transducer elevationally at controlled intervals for a more robust evaluation 
of therapy effectiveness (40, 28). Finally, we compare and elucidate the strength of each 
technique as a tool to classify responders and non-responders and to characterize how a 
tumor will respond to therapy over time in our PDX models.
Materials and Methods
Microbubble Contrast Agents (MCAs)
MCAs designed to target αvβ3 integrins were created with a 9:0.5:0.5 molar ratio of 1,2 
Distearoyl- sn-Glycero-3-Phosphocholine (DSPC) (Avanti Polar Lipids - Alabaster, AL), 
1,2-Distearoyl-sn-Glycero-3-Phosphoethanolmine-N–Methoxy-Polyethylene Glycol-2000 
(DSPE-PEG2000) (Avanti Polar Lipids – Alabaster, AL), and DSPE-PEG2000 cross-linked 
to a cyclic RGD peptide (Cyclo-Arg-Ala-Asp-D-Tyr-Cys) (Peptides International - 
Louisville, KY) as previously described (29). The chosen cyclic RGD peptide has 
previously been shown to target αvβ3-expressing vasculature, which is characteristic of 
angiogenic tumors (44, 29, 28). MCAs with a large preferentially selected mean diameter 
(~3.9 µm) have been shown to produce greater backscatter intensities in molecular imaging 
studies as compared to vial-shaken unsorted polydisperse distributions (29, 45); therefore, 
all MCAs in this study were size-selected via the method as presented by Feshitan and 
colleagues (46). Unsorted non-targeted MCAs for perfusion imaging were created with a 
similar lipid formulation, but without the targeting ligand.
Animal Preparation and Contrast Administration
Two PDXs were chosen for this study, one with known response to MLN8237 (PDX-R) and 
one with no response (PDX-NR) to MLN8237 based on tumor size measurements and long-
term growth curves in previous studies. Each PDX (PDX-R and PDX-NR) was expanded 
into 14 nude mice (PDX-R & PDX-NR: Mean Volume ~ 0.2 ± 0.1 cm3). Seven mice were 
then assigned to drug treatment or vehicle groups for both USMI and DCE-PI experiments. 
All animal studies were performed in accordance with protocols approved by the University 
of North Carolina School of Medicine Institutional Animal Care and Use Committee. 
During ultrasound imaging studies, animals were anesthetized with ~2% inhaled isoflurane 
anesthesia with oxygen and their body temperature was maintained at 37° C through the use 
Streeter et al. Page 4













of a temperature-controlled heating pad. The area to be imaged was coupled to the 
ultrasound transducer using a water-based acoustic coupling gel devoid of any air bubbles. 
A 27-gauge catheter was inserted into the tail vein of the animal for the administration of 
MCAs. In all USMI experiments, bolus MCA injections of 50 µL (Concentration: 1×108 
MCAs/mL) were delivered followed by an immediate flush of at least 50 µL sterile saline to 
clear any remaining MCAs from the catheter. For all DCE-PI experiments, non-targeted 
MCAs were continuously infused at a rate of 15 µL/min using a PHD-2000 syringe pump 
(Harvard Apparatus – Holliston, MA).
Therapy
A total of 28 nude mice (N=14 PDX-R and N=14 PDX-NR’s) were used for USMI and 
DCE-PI experiments. Animals were either treated with 30 mg/kg of MLN8237 or a vehicle 
control daily by oral gavage over a 14-day period. For all experiments, USMI and DCE-PI 
data were taken on day 0, day 2, day 7, and day 14 during the treatment period in the same 
animals.
3-D Imaging Apparatus
A Siemens Sequoia imaging system (Acuson Sequoia 512 – Mountainview, CA) with a 
linear array transducer (Model # 15L8) was used to acquire all ultrasound images in both 
USMI and DCE-PI studies. To create 3-D data sets, the transducer was scanned 
elevationally using a linear motion stage (Model UTS150PP, Newport – Irvine, CA). A 
custom LabView (National Instruments – Austin, TX) program was interfaced to both the 
motion stage and the ultrasound system, enabling the control of step-sizes, and triggering the 
capture of video data at every discrete step as previously described by Feingold et al and 
Streeter et al (28, 40).
Ultrasonic Molecular Imaging
Cadence pulse sequencing (CPS) mode was used in all studies (USMI and DCE-PI). CPS is 
a non-destructive contrast-specific imaging mode developed by Siemens, which has been 
used for both perfusion and molecular imaging (47). Prior to imaging tumors with targeted 
contrast agents, background data was taken in both b-mode and CPS mode to optimize 
elevational scan length and to ensure the absence of bubbles within the coupling gel. After 
the initial background scans were performed, the system was paused and a 50 µL bolus 
injection of contrast agents was administered through the catheter followed by a 50 µL flush 
with sterile saline. After waiting approximately 15 minutes for freely-circulating bubbles to 
clear from the animal’s system, a 3-D imaging scan was acquired across the tumor with 
inter-plane step sizes of 400 µm in the ultrasound system’s CPS mode. The bound 
microbubbles were then destroyed using a high mechanical index b-mode volumetric scan, 
and then the tumor was re-imaged in CPS mode at the same slice locations for a baseline 
measurement with no targeted agents. Within each data set, the system receive gain (−15 
dB), and transmit power (MI: 0.18) were kept constant and the axial focus was always 
positioned in the center of the tumor for each animal’s readpoints. The time required for 
each molecular imaging study was approximately 30 minutes per animal.
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Video data from targeting experiments were acquired and saved in compressed DICOM 
format for offline analysis. Using b-mode image data collected prior to contrast 
administration, ROIs were established around the perimeter of the tumor in each image 
plane. With custom MATLAB scripts, the difference in mean pixel intensity between the 
pre-destruction pulse image (the image with adherent MCAs) and the background image 
was determined for each image plane as a measure of αvβ3 targeting, similar to previous 
molecular imaging studies with ultrasound (29, 28).
Dynamic Contrast Enhanced - Perfusion Imaging
DCE-PI was performed by using the destruction-reperfusion imaging technique previously 
described by Wei et al (32) and real-time motion correction was performed as described by 
Pollard et al (34). The “CPS Capture” software tool was used to implement this technique. 
Briefly, non-targeted contrast agents were continuously infused at a rate of 15 µL/min. After 
a wait period of one minute for complete tumor perfusion, a contrast specific frame was 
collected and recorded by the system. Then, a short high-intensity pulse of ultrasound that 
causes rapid destruction of MCAs in the 2-D imaging plane was introduced. This clearance 
pulse was immediately followed by a low-intensity contrast specific interrogation to monitor 
the MCAs as they entered back into the tissue. When the monitored contrast signal reached 
20% (Time to 20% - TT20) of the previously recorded image, the time was recorded and 
displayed as a color. Perfusion mapping occurred at the pixel level and the maximum 
perfusion time window was set to be 20 seconds for all readpoints. Within each data set, the 
system receive gain (−15 dB), and transmit power were kept constant. Perfusion imaging 
studies required approximately 10 minutes per animal.
Video data from perfusion imaging experiments were acquired and saved in compressed 
DICOM format for offline analysis. Using the b-mode image data collected during the MCA 
destruction sequence, ROIs were established around the perimeter of the tumor in each 
image plane. With custom MATLAB scripts, the mean pixel intensity, which is linearly 
related to the time that it takes to reach 20% of the pre-destructive value, was averaged for 
all voxels throughout the perfused volume of the treated tumor.
Volume Measurements
Volume measurements for each tumor were obtained using the b-mode images acquired 
during USMI experiments in conjunction with the elevational step size.
Statistical Analysis
For USMI experiments, the amount of microbubble targeting for the volume of the tumor 
was quantified as the difference between the mean pixel intensity within the user-defined 
volume with targeted microbubbles and the mean pixel intensity of the volume after the 
MCAs were destroyed. At each readpoint, the amount of microbubble targeting was 
normalized to the value obtained at baseline (day 0).
For DCE-PI experiments, the time that it takes to reach 20% of the pre-destructive value was 
averaged for all voxels throughout the volume of the treated tumor. At each readpoint, the 
volumetric perfusion time was normalized to the value obtained at baseline (day 0).
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Likewise, for volume experiments, the measured volume at each readpoint was normalized 
to the value obtained at day 0.
Significance between treated and untreated distributions was analyzed in Excel using a two-
sided student’s t-test with unequal variance. Significance between distributions were 
considered at a value of p < 0.05.
Results
Ultrasonic Molecular Imaging
PDX-R—Day 2 was the earliest readpoint at which there was a statistical difference 
between the untreated and treated populations when using USMI. On day 2, the mean 
volumetric targeted microbubble intensity in treated animals decreased by 51% from the 
baseline measurement at day 0 compared to an 20% increase in targeting for untreated 
animals (Untreated: 1.20±0.53 vs. Treated: 0.49±0.40; p < 0.05) (Figure 1A). On Day 7, the 
same trend was observed (Untreated: 0.70±0.31 vs. Treated: 0.08±0.09; p < 0.05), however, 
by day 14, there were no discernible differences between treated and untreated populations.
Volumetric ultrasound images of a representative treated and a representative untreated 
PDX-R at baseline and 48 hours after treatment are illustrated in Figure 2. Axial and lateral 
axes are displayed on each 3-D image to orient the reader to the plane of the ultrasound 
transducer. In addition, 2-D cross sections, as registered by these section axes, illustrate the 
level of targeting at each day for the treated and untreated animal. The green color overlay 
illustrates the microbubble adherence to αvβ3 where the brightness is assumed to be 
correlated with the degree of molecular marker expression.
PDX-NR—In the PDX-NR cohort, there were no significant differences between treated 
and untreated populations at any readpoint in the 14-day study (Figure 1B). For clarity, 
Table I provides the volumetric USMI data for both the PDX-R and PDX-NR cohorts at all 
readpoints.
Dynamic Contrast Enhanced - Perfusion Imaging
PDX-R—Day 14 was the earliest readpoint at which there was a statistical difference 
between the untreated and treated populations when using DCE-PI. Of note, by day 2 there 
was an increase in mean volumetric TT20 values relative to day 0. While there was not a 
significant difference between treated and untreated populations at this readpoint, there was 
an increasing difference between treated and untreated population until day 14. As will be 
shown in the following subsection, this trend was not observed in the PDX-NR cohort. On 
day 14, the mean volumetric TT20 value increased by 31% from baseline in treated animals 
compared to a 6% decrease in the TT20 for untreated animals (Untreated: 0.94±0.23 vs. 
Treated: 1.31±0.22; p < 0.05) (Figure 3A).
PDX-NR—There were no significant differences between treated and untreated populations 
at any readpoint with the PDX-NR cohort (Figure 3B). Table II provides the raw volumetric 
DCE-PI values for each group at each readpoint.
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PDX-R—In the PDX-R cohort of animals, there was no statistical difference between 
treated and untreated populations when measuring the volume of the tumor at any readpoint 
(Figure 4). However, the difference in tumor volume between treated and untreated animals 
began to increase starting at day 7, as would be expected in this PDX-R, since it is 
characterized by known response to MLN8237 treatment. This trend was not observed in the 
PDX-NR cohort.
PDX-NR—As with the PDX-R group, there was no observed statistical difference between 
treated and untreated populations when measuring the volume of the tumor at any readpoint. 
Table III summarizes the volume data collected for the responder and non-responder groups.
Discussion and Conclusion
In this study, USMI of angiogenesis showed a statistical difference between treated and 
untreated PDX-R populations after 48 hours of treatment. In contrast, there was no 
significant difference between treated and untreated groups at the same readpoints in the 
PDX-NR cohort. Thus, our USMI study clearly illustrates the viability of the technique for 
monitoring the response to therapy and classifying and characterizing tumors as responders 
and non-responders in pre-clinical evaluations where comparison with a baseline untreated 
control is available. In addition, this imaging method used for monitoring biomarker 
expression was the earliest of the three tested techniques in detecting a change, as reflected 
by the time at which change was detected (48 hours) and the statistical significance between 
groups (p = 0.03) in the PDX-R cohort.
Data illustrate that the degree of αvβ3 expression decreased at a faster rate for treated 
animals as compared to untreated animals in the PDX-R group, which was the observed 
trend over a 7-day window (−12% vs. −5%). Likewise, the PDX-NR group also experienced 
this trend, though the treated group was not significantly different from the untreated group 
(−4% vs. −2%, p = 0.08). This data may suggest that the PDX-NR group partially responded 
to the therapy, which may explain why we were unable to differentiate between the treated 
responder group and the treated non-responder group without normalizing to the untreated 
control cohorts.
DCE-PI, which is a measurement of vascular perfusion and thus MVD, showed statistical 
significance on day 14 between treated and untreated populations in the PDX-R cohort. 
Thus, USMI provided information about therapy response prior to DCE-PI for the PDX-R 
group. This result was not unexpected, as changes in the microvasculature are likely 
preceded by a corresponding change in biomarker expression. Furthermore, it was predicted 
that healthy vasculature would have faster perfusion times relative to unhealthy 
microvasculature, which was the observed outcome in the DCE-PI study. (48, 49) Data 
illustrated that the perfusion times increased at a faster rate during treatment compared to 
untreated tumors, which was observed in our study (2% vs. 0%). Based on our results, DCE-
PI appears to be a viable alternative to volume measurements in terms of classification and 
characterization of responder and non-responder cohorts for pre-clinical evaluations.
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Using volume measurements for therapeutic pre-clinical mouse model studies is rapid, non-
invasive and inexpensive; however, it is also high in variability, which is an impediment as a 
means for monitoring the response to therapy (50, 51). In this study, volume measurements 
obtained with ultrasound did not show any significant differences between treated and 
untreated groups on any day for either the PDX-R or PDX-NR cohorts. In contrast, USMI 
and DCE-PI both demonstrated their ability to detect changes between treated and untreated 
populations in the responder group at earlier time points than with volume measurements. 
As with the DCE-PI technique, the volume curves for the treated and untreated treatment 
populations of the PDX-NR cohort during the time period of the imaging study provided no 
evidence to support that there was a partial response to therapy.
There are a number of factors that could have impacted how the evaluated techniques 
performed in this study. For instance, the strength of the evaluated therapeutic may favor 
one method over the other in terms of the measured effect. The stronger the therapeutic, the 
more likely the method may detect a change at earlier time points. An increase in dose was 
not evaluated in this study. Secondly, the readpoint sampling may have contributed to the 
observed performance of the DCE-PI study. If imaging was performed more frequently 
between day 2 and day 14, then more observed days with a significant difference between 
populations might have been observed prior to day 14. The tumor type may also have 
contributed to the performance of each technique. In the pancreatic adenocarcinoma tumor 
model that was used in this study, necrosis was observed to increase throughout the length 
of the study. As a tumor becomes more necrotic, it also becomes less vascular, which 
ultimately makes the untreated groups look similar to the treated groups. For instance, the 
untreated populations (PDX-R group) in our USMI study showed a gradual decrease in αvβ3 
expression. This decrease over time can mean one of two things. Either the vessels are not 
expressing the angiogenic biomarker or there is not a vessel there to express the biomarker, 
which is more likely given that areas of necrosis were also observed in the DCE-PI study. 
Thus, as the untreated tumor becomes more naturally necrotic over time, it confounds the 
ability of the technique to distinguish between the treated and untreated groups. In future 
studies, for both USMI and DCE-PI, each of these factors must be explored. Finally, 
significance of this study was limited due to its short-term observation period. Future work 
will need to include larger subject numbers and longer time scales to more thoroughly 
validate our preliminary observations.
In order to evaluate the sensitivity of each technique’s ability to identify a responder over a 
non-responder in a clinical situation, we evaluated the significance between treated groups at 
each readpoint. None of the evaluated techniques showed a statistically significant 
difference between treated groups (PDX-R treated vs. PDX-NR treated) at any readpoint. 
Our study indicated that normalization relative to the untreated groups needed to be 
performed to illustrate the significance of the data. Since normalization would not be 
relevant in a clinical situation, the methods as described here would not be clinically 
translatable without further improvement. Nevertheless, USMI and DCE-PI have illustrated 
substantial potential in pre-clinical response to therapy studies. Furthermore, it is very 
possible that these techniques still may be clinically significant without normalization in 
different tumor models or with different therapeutic approaches, or after further 
improvements in imaging and contrast agent technology.
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In conclusion, we showed that we could successfully classify a tumor as a responder or a 
non-responder with both USMI (day 2 & day 7) and DCE-PI (day 14) and at earlier time 
points than with volume measurements (~4 weeks). Second, we were able to characterize 
how the PDX-R and PDX-NR groups would respond over a 14-day period, which is an 
essential component in understanding the pathophysiologic mechanisms of a particular type 
of cancer and it is an evolutionary step for a clinical-type application. Based on our results, 
we feel that classification and characterization of a tumor in pre-clinical evaluations using 
USMI may allow for more effective drug development and an improvement in 
pharmacodynamic monitoring through reduced cycle times. Finally, since a volumetric 
approach has been shown to provide more accurate data than an equivalent 2-D analysis, we 
have succeeded in illustrating the strengths of 3-D USMI and 3-D DCE-PI for characterizing 
a tumor’s response to therapy in pre-clinical studies.
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A) The percent change in volumetric targeted microbubble intensity for treated and 
untreated animals before and after therapy in a tumor type that responds to MLN8237 
(N=7). B) The percent change in volumetric targeted microbubble intensity for treated and 
untreated animals before and after therapy in a tumor that does not respond to MLN8237 
(N=7). * p < 0.05 for treated group relative to untreated group.
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3-D ultrasound images of a representative treated and a representative untreated tumor 
(PDX-R). A (axial) and L (lateral) axes are displayed to orient the reader to the traditional 
ultrasound b-mode image plane. 2-D cross sections as registered by these section axes are 
displayed in the central region of each panel. The green color overlay illustrates the 
microbubble adherence to αvβ3, an angiogenic biomarker. The brightness of the green image 
overlay is assumed to be correlated with the degree of molecular marker expression.
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A) The average volumetric perfusion times before and after therapy for treated and untreated 
animals in a tumor type that responds to MLN8237 (N=7). B) The average volumetric 
perfusion times before and after therapy for treated and untreated animals in a tumor type 
that does not respond to MLN8237 (N=7). * p < 0.05 for treated group as compared to 
untreated group.
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A) The tumor volume as measured by regions of interest from ultrasound b-mode for treated 
and untreated animals in a tumor known to respond to MLN8237 (N=7). B) The tumor 
volume as measured by regions of interest from ultrasound b-mode for treated and untreated 
animals in a tumor known not to respond to MLN8237 (N=7).
Streeter et al. Page 17


























































































































































































































































































































































































































































































































































































































































































































































Technol Cancer Res Treat. Author manuscript; available in PMC 2015 May 14.
